Provided by Tiger Fintech (Singapore) Pte. Ltd.

Arvinas Holding Company LLC

8.60
+0.950012.42%
Post-market: 8.620.0200+0.23%19:56 EDT
Volume:3.19M
Turnover:26.35M
Market Cap:591.44M
PE:-3.11
High:8.64
Open:7.74
Low:7.61
Close:7.65
Loading ...

Arvinas Inc - Plans to Initiate Two Phase 3 Trials for Vepdegestrant Combos in 2025

THOMSON REUTERS
·
11 Feb

Arvinas- Expects Cash, Cash Equivalents & Marketable Securities as of Dec 31, 2024, to Fund Planned Operating Expenses & Capex Requirements Into 2027

THOMSON REUTERS
·
11 Feb

Arvinas Says Its Cash, Cash Equivalents, And Marketable Securities Of $1.04B As Of December 31, 2024, Is Sufficient To Fund Planned Operating Expenses And Capital Expenditure Requirements Into 2027

Benzinga
·
11 Feb

Arvinas Q4 2024 GAAP EPS $(0.63) Beats $(0.87) Estimate, Sales $59.20M Miss $65.28M Estimate

Benzinga
·
11 Feb

BRIEF-Arvinas Q4 Basic EPS USD -0.63 Vs. IBES Estimate USD -1.02

Reuters
·
11 Feb

Arvinas Q4 Operating Expenses USD 117.4 Million

THOMSON REUTERS
·
11 Feb

Arvinas Is Maintained at Overweight by Barclays

Dow Jones
·
03 Feb

Arvinas Inc : Leerink Partners Cuts Target Price to $49 From $62

THOMSON REUTERS
·
03 Feb

Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025

GlobeNewswire
·
03 Feb

Arvinas price target lowered to $32 from $48 at Barclays

TIPRANKS
·
03 Feb

Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN) and VolitionRX (VNRX)

TIPRANKS
·
24 Jan

Arvinas Inc - on Jan 15, Unit Enters Lease Termination Agreement With Science Park Development

THOMSON REUTERS
·
22 Jan

Arvinas Shares Fall Amid Breast Cancer Drug Trial Update, CCO Departure

MT Newswires Live
·
11 Jan

Arvinas updates milestones for 2025

TIPRANKS
·
10 Jan

Arvinas Inc - Topline Data From Veritac-2 Phase 3 Trial Expected in 1Q25

THOMSON REUTERS
·
10 Jan

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials With Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

THOMSON REUTERS
·
10 Jan

Arvinas Inc - Second-Line Phase 3 Trial of Vepdegestrant and Cdk4/6 Inhibitor to Initiate in 2025

THOMSON REUTERS
·
10 Jan

Arvinas Inc - Phase 3 Trial of Vepdegestrant and Atirmociclib to Initiate in 2025

THOMSON REUTERS
·
10 Jan

Arvinas (NASDAQ:ARVN) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
25 Dec 2024

Barclays Keeps Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
13 Dec 2024